BioWorld

May 16, 2002

Tranzyme Enters QBI Deal, Targets Neurosensory Drugs

Hyseq, BASF To Finish Deal Early; Hyseq Cutting Employees

Second-Generation LongSAGE' Strategists Say 15,000 Genes In Human Genome Still Uncounted

Nexell's Board OKs Orderly Wind-Down' Of Operations

Other News To Note

Corixa Wants Dispute Resolution For Bexxar Through FDAMA

Corixa Corp. said it is requesting an appeal of the FDA's complete review letter questioning the net clinical benefit and safety of the company's lead cancer product, known as Bexxar. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 22, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Nankai University and Accendatech present new majusculamide D derivatives

BioWorld Science

Scientists from Nankai University Tianjin and Accendatech Technology Co. Ltd. have identified a majusculamide D derivative found to be useful for the treatment of...

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...